Plus, more stories from AAD and ACC Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 30 March, 2026

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

news Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma Kailera plans IPO to raise money for its China-licensed obesity pipeline Exclusive: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure Biogen declares Phase 2 lupus success for anti-BDCA2 antibody Merck leans toward lower Winrevair dose for pivotal trial in rare form of heart failure

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Every year, John Carroll sizes up the top 15 global pharma pipelines — then brings the findings live with the R&D chiefs shaping them. What's in, what's out, and what's next for 2026? Register now.

ENDPOINTS PHARMA Top Trump health official describes 'war' with China over biotech After years of setbacks, FDA approves Rocket's gene therapy for ultra-rare immune disease CHMP recommends subcutaneous form of Sanofi's Sarclisa and four new drugs Novo Nordisk gets FDA go-ahead for weekly insulin after three-year wait

in case you missed it 1. Otsuka acquires private neuropsych biotech Transcend for $700M upfront 2. AstraZeneca’s in vivo CAR-T showed promise against multiple myeloma, but also one death in China trial 3. Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate 4. Peer Review Recursion appoints former Exelixis CMO; More executive moves at Incyte 5. AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population 6. News Briefing AnaptysBio spins out biotech operations; Affibody's data in hidradenitis suppurativa 7. Eli Lilly pushes for NHS drug price increases in return for its UK investment